Abstract
Fish oils (FOs) have anti-inflammatory effects and lower serum triglycerides. This study examined adipose and muscle inflammatory markers after treatment of humans with FOs and measured the effects of ω-3 fatty acids on adipocytes and macrophages in vitro. Insulin-resistant, nondiabetic subjects were treated with Omega-3-Acid Ethyl Esters (4 g/day) or placebo for 12 weeks. Plasma macrophage chemoattractant protein 1 (MCP-1) levels were reduced by FO, but the levels of other cytokines were unchanged. The adipose (but not muscle) of FO-treated subjects demonstrated a decrease in macrophages, a decrease in MCP-1, and an increase in capillaries, and subjects with the most macrophages demonstrated the greatest response to treatment. Adipose and muscle ω-3 fatty acid content increased after treatment; however, there was no change in insulin sensitivity or adiponectin. In vitro, M1-polarized macrophages expressed high levels of MCP-1. The addition of ω-3 fatty acids reduced MCP-1 expression with no effect on TNF-α. In addition, ω-3 fatty acids suppressed the upregulation of adipocyte MCP-1 that occurred when adipocytes were cocultured with macrophages. Thus, FO reduced adipose macrophages, increased capillaries, and reduced MCP-1 expression in insulin-resistant humans and in macrophages and adipocytes in vitro; however, there was no measureable effect on insulin sensitivity.
Trial registration:
ClinicalTrials.gov NCT00579436.
Publication types
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Abdominal Fat / blood supply
-
Abdominal Fat / immunology*
-
Abdominal Fat / metabolism
-
Abdominal Fat / pathology
-
Angiogenesis Inducing Agents / metabolism
-
Angiogenesis Inducing Agents / therapeutic use
-
Anti-Inflammatory Agents, Non-Steroidal / metabolism
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Body Mass Index
-
Capillaries / immunology
-
Capillaries / metabolism
-
Capillaries / pathology
-
Cells, Cultured
-
Chemokine CCL2 / blood
-
Chemokine CCL2 / genetics
-
Chemokine CCL2 / metabolism
-
Coculture Techniques
-
Dietary Supplements*
-
Docosahexaenoic Acids
-
Down-Regulation
-
Drug Combinations
-
Eicosapentaenoic Acid
-
Fatty Acids, Omega-3 / metabolism
-
Fatty Acids, Omega-3 / therapeutic use*
-
Female
-
Fish Oils / therapeutic use
-
Humans
-
Insulin Resistance*
-
Macrophages / immunology*
-
Macrophages / metabolism
-
Macrophages / pathology
-
Male
-
Metabolic Syndrome / complications
-
Metabolic Syndrome / diet therapy*
-
Metabolic Syndrome / immunology
-
Metabolic Syndrome / metabolism
-
Middle Aged
-
Muscles / immunology
-
Muscles / metabolism
-
Muscles / pathology
-
Obesity / complications*
-
RNA, Messenger / metabolism
Substances
-
Angiogenesis Inducing Agents
-
Anti-Inflammatory Agents, Non-Steroidal
-
CCL2 protein, human
-
Chemokine CCL2
-
Drug Combinations
-
Fatty Acids, Omega-3
-
Fish Oils
-
RNA, Messenger
-
Docosahexaenoic Acids
-
Eicosapentaenoic Acid
-
Omacor
Associated data
-
ClinicalTrials.gov/NCT00579436